During the past decade it was recognized that homeobox gene families such as the clustered Hox genes play pivotal roles both in normal and malignant hematopoiesis. 
Introduction
The last decade has seen large advances in our understanding of the regulatory network in prenatal and adult hematopoiesis. As one pivotal class of regulatory factors the highly conserved family of homeobox genes have been identified as playing major roles not only in normal hematopoiesis but also in leukemogenesis 1 . The homeobox was first identified in the 1980s as a sequence motif shared among Drosophila homeotic genes (the HOM-C complex) which play key roles in embryonic differentiation along the anterior-posterior axis. The existence of homeotic genes was already proposed in the early 1900s based on observations of Drosophila mutants with changes in the body structure 2 . The homeobox is now known to be present in many genes in virtually all eukaryotic species 3 . It is estimated that the human genome contains at least 200 homeobox genes 4 . Unlike the HOM-C/HOX genes, which are organized in gene clusters, most homeobox genes are dispersed throughout the genome [5] [6] . Homeoboxcontaining genes constitute a gene family characterized by a highly conserved 183-nucleotide sequence encoding a 61-amino acid domain, the homeodomain (HD). These homeodomains are structurally related to the helix-turn-helix motif of prokaryotic DNAbinding proteins and have sequence-specific DNA binding activity 7 . Homeobox genes are divided into two classes. Class I includes clustered genes (HOX) that comprises 39 members, while the Class II divergent homeobox genes are dispersed through the genome and include smaller families such as the MSX, ParaHox (CDX), PAX, DLX and Engrailed (EN) groups. Although individual members of homeobox families often share little sequence similarity other than the homeobox, some families have additional conserved sequence motifs that contribute to their distinct functional properties 5, 8 . A key role of homeobox genes for normal and malignant stem -and progenitor cell For personal use only. on September 13, 2017. by guest www.bloodjournal.org From behavior was first shown for Hox genes. Initial hints that these genes are essential for regulating hematopoietic stem cells (HSCs) and progenitor cells came from data showing that Hox genes of the A and B cluster are highly expressed in normal murine and human hematopoietic stem (HSCs) and progenitor cells, but silenced in their more differentiated progeny [9] [10] . Studies in experimental models have convincingly proven the functional relevance of Hox genes for normal hematopoietic behavior in mouse and man: e.g. Hoxa9 -/-bone marrow cells manifest a severe defect at the level of HSCs and committed progenitors [11] [12] ; on the other hand aberrant expression of Hox/HOX genes such as Hoxa9 or Hoxa10 can induce acute myeloid leukemia (AML) in mice, whereas constitutive expression of Hoxb4 increases the self-renewal capacity of murine HSCs without initiating leukemic transformation [13] [14] [15] . Similar data were obtained for the human system using retroviral gene transfer techniques and the NOD/SCID xenograft model [16] [17] . Early data revealed aberrant expression of HOX genes in patients with acute leukemia 18 and this was confirmed later by microarray analyses in large cohorts of patients with AML thereby associating aberrant expression of HOX genes such as HOXA9 with clinical outcome [19] [20] [21] [22] . The rich body of data on the role of Hox genes in normal and malignant hematopoiesis has been reviewed in detail before 1, [7] [8] 23 . In the last years, however, it was shown that other homeobox genes, not belonging to the 25 . This review will focus on another homeobox gene family, the ParaHox cluster, which was shown to be involved in normal as well as malignant hematopoiesis 6, 24 .
The ParaHox cluster genes: emerging key players in normal and malignant hematopoiesis

Genomic organization and molecular characteristics
The ParaHox gene cluster was discovered in 1998 by Brooke et al. who reported that Gsx (genomic screened homeobox), Xlox (Xenopus laevis homeobox) and Cdx (Caudaltype homeobox) genes form their own cluster in the cephalochordate amphioxus. This cluster was termed the ParaHox cluster as it showed homology to the different paralogue groups of the Hox cluster 26 . In mice and man homologous genes cluster on chromosome 5 and 13q12, respectively: these comprise the genes Gsh1/GSH1, Xlox/XLOX (also known as Pdx1/PDX1) and CDX2 [27] [28] . In contrast to chordates, mammals have additional ParaHox genes, namely Gsh2/GSH2, Cdx1/CDX1 and Cdx4/CDX4, which are spread over three different chromosomes in the human genome (table 1) (Fig.1a) The ParaHox and Hox clusters are thought to originate from an ancient hypothetical ProtoHox cluster by duplication before the split of protostomes and deuterostomes, characterizing the ParaHox cluster as one of the evolutionary early homeobox gene clusters 6, [29] [30] . This also explains the homologies of the ParaHox genes to paralogue 6, 30 . The Gsx gene is more closely related to Hox 'Anterior Group' genes than to other ParaHox genes; Xlox is more similar to Hox 'Group 3', and Cdx is more similar to the Hox 'Posterior Group' genes.
Structure -functional analyses have characterized the molecular characteristics of ParaHox proteins in detail (table 1) (Fig.1b) [36] [37] [38] . In contrast to Cdx2, Cdx4-null murine embryos are born healthy and do not show any major morphological or histological abnormalities 39 .
Cdx2 and Cdx4 are key regulators of embryonic hematopoiesis
Over the past several years it has become evident, that ParaHox Cdx family members are critical for ordered proliferation and differentiation of embryonic hematopoietic cells 40 . This was particularly demonstrated for the Cdx genes Cdx4 and Cdx2. Evidence for a key role of Cdx genes in embryonic hematopoiesis initially came from studies in zebrafish: homozygous mutations in cdx4 caused a severe defect in embryonic For personal use only. on September 13, 2017. by guest www.bloodjournal.org From hematopoiesis with a profound reduction of hemoglobin positive erythroid cells resulting in severe anemia 41 . These blood defects were accompanied by deregulated or reduced expression of hoxb4, hoxb5a, hoxb6b, hoxb7a, hoxb8a, hoxb8b and hoxa9a. Of note, the blood deficiency in zebrafish embryos could be rescued by overexpression of hoxb7a or hoxa9a but not by scl, indicating that the hematopoietic defect is at least partly caused by perturbation of distinct Hox genes 41 . The same group demonstrated that morpholino-mediated knockdown of cdx1a in a cdx4 mutant background caused a severe perturbation of Hox gene expression and a complete failure to specify blood in zebrafish. Furthermore, these Cdx-deficient embryos displayed a significant reduction in expression of key hematopoietic genes such as scl, runx1, and gata1
42
. This hematopoietic defect could be efficiently rescued by hoxa9 overexpression, but not by hoxb7 42 .
In mouse, ectopic expression of Cdx4 enhances hematopoietic mesoderm formation and further promotes blood progenitor specification and hematopoietic engraftment of murine embryonic stem cells (ESCs) in adult mice 43 . In addition, Cdx4 overexpression rescues defective blood progenitor formation in mouse ESCs deficient in Mll, a Hox regulator involved in definitive hematopoiesis 44 . Surprisingly, Cdx4 knock-out mice do not show any major hematopoietic defects 45 . Indeed, in both germline and conditional Cdx4 knockout models, there is no apparent defect in HSC and progenitor cells as well as mature blood cells. This indicates that Cdx4 as a single factor is not essential for normal adult hematopoietic stem cell functions in mice and that Cdx4 function can be compensated at least partly by other Cdx genes 45 . One candidate for this is Cdx2: Cdx2-deficient ESCs show impaired production of multipotential blood progenitor colonies in vitro consistent with an essential role of Cdx2 in early embryonic hematopoiesis 46 . By Taken together, these data demonstrate that Cdx genes play essential and both distinct and overlapping roles in embryonic hematopoiesis.
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ParaHox genes in malignant hematopoiesis
ParaHox genes have emerged as pivotal players in leukemogenesis with a rich body of evidence linking aberrant expression of the ParaHox gene Cdx2 and other ParaHox genes to acute leukemia (table1) (Fig.2) .
GSH2
The Gsh2 gene was previously characterized as a brain-specific ParaHox gene important in forebrain and hindbrain formation of the mouse. Peter Marynen's group has shown that GSH2 is not expressed in adult human normal hematopoietic cells. However the group has reported ectopic expression of GSH2 in four patients with AML carrying the translocation t(4;12)(q11-q12;p13), which itself generated no detectable fusion gene.
GSH2 is located at 4q11-q12 and thus located closely to the respective breakpoint, which implies that the translocation induces ectopic expression of GSH2. Indeed the authors could demonstrate that aberrant expression of GSH2 caused focus formation in the NIH3T3 assay as a surrogate marker for the oncogenic potential of this ParaHox gene 48 .
Cdx1
In normal adult hematopoietic tissue, expression of this homeobox gene was not reported so far and there are no data suggesting involvement of Cdx1 in malignant hematopoiesis. However, in the adult Cdx1 is known to be involved in the intestinal differentiation and the development of intestinal metaplasias [49] [50] [51] . . Later we and others have reported that CDX2 is aberrantly expressed in more than 80% of human AML patients, characterizing CDX2 as one of the most frequent aberrantly expressed proto-oncogenes in human leukemia (Fig. 2 ).
Aberrant expression of CDX2 was found in all types of cytogenetic subgroups. Scholl et al. reported the highest expression of CDX2 in patients with t(9;11) followed by normal karyotype AML (CN -AML) and t(15;17) positive patients, similar to our results with highest expression of CDX2 in CN-AML followed by t(9;11) and t(15;17) positive cases [55] [56] . Aberrant expression of CDX2 was not only more common in patients with CN-AML compared to patients with abnormal karyotype (89% vs. 64%, respectively), but the expression level of CDX2 was significantly and more than 15-fold higher in patients with . The expression level of CDX2 in ALL patients significantly correlated with treatment outcome (high expression levels were associated with inferior overall survival) of the analyzed patients. Although this study was limited by a low number of patients, CDX2 remained an independent risk factor even after adjusting for the risk factors age and presence of molecular markers by bivariate Cox regression 58 . These data were confirmed for pediatric ALL where the vast majority of patients also showed aberrant expression of CDX2. Also in this study, 1 3 aberrant expression of CDX2 significantly correlated to an inferior disease outcome 59 .
Another recent independent study reported CDX2 expression in 61% of de novo adult ALL patients and decrease of CDX2 expression in patients with complete remission and increase in relapse 60 . Similar to AML the mechanism of aberrant CDX2 expression in ALL is not understood. We have not identified any difference in the methylation level of the CDX2 promoter in CDX2-positive and -negative ALL patients 58 . In contrast to AML, where aberrant CDX2 expression correlated with HOX gene deregulation, there was only a low correlation between the expression of HOX genes with the expression of CDX2, in line with reports that HOX gene deregulation is less common in ALL than in AML [61] [62] . Taken together, these data link aberrant expression of CDX2 to myeloid as well as lymphoid leukemia. So far it is unknown, whether the stage of differentiation of the cell, which is initially hit by aberrant CDX2 expression, determines the phenotype of the leukemia. Experiments testing whether aberrant expression of CDX2 in lymphoid progenitor cells generates ALL in mice are lacking so far.
Cdx2 is highly leukemogenic in experimental models
In a murine BM transplantation model it was shown that ectopic expression of the Parahox gene CDX2, but not expression of the fusion gene ETV6/CDX2, which was described in a patient with translocation t(12;13)(p13;q12) positive AML 37, 64 . The ability to upregulate Hox gene expression and to induce AML was clearly dependent on the N-terminal transactivation domain of Cdx2, known to harbor serine phosphorylation sites, which affect the transcriptional activity of the gene 55, 65 . Interestingly, the ETV6-CDX2 fusion gene also lacks the N-terminal transactivation domain of CDX2, which would explain the obvious discrepancy of the oncogenic potential between Cdx2 and the ETV6-CDX2 fusion.
Aberrant Cdx2 expression also led to an altered expression of a number of genes involved in lymphopoiesis such as Lef1, Tcf3 or Id3. These genes are frequently deregulated in lymphoid leukemia 58, [66] [67] and are able in the case of Lef1 to induce ALL in transplanted mice 55 .
The vast majority of data on the leukemogenicity of Cdx2 comes from murine models.
However, at least at the level of human leukemia cell lines it could be demonstrated, that leukemic growth depends on aberrant CDX2 expression: thus, shRNA mediated depletion of CDX2 in the human pre-B cell line Nalm-6 and several AML cell lines significantly impaired leukemic cell proliferation and clonogenicity 56, 58 .
CDX4 is less leukemogenic than Cdx2
It has been shown that overexpression of Cdx4 confers enhanced replating and proliferative potential to transduced murine hematopoietic cells. Mice transplanted with
Cdx4 overexpressing bone marrow developed a myeloproliferative disorder, which In AML patients CDX4 is expressed aberrantly in approximately 25% of all cases. CDX4 expression, however, did not correlate to a certain leukemia subtype and its expression did not correlate to HOX gene deregulation 68 . This finding suggests that the ability of CDX4 to deregulate HOX gene expression is of minor relevance for its role in human leukemia.
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Mechanisms of ParaHox induced leukemogenesis -speculations and future directions
Gene expression profiling and functional data clearly support a critical involvement of CDX2 in human leukemogenesis. However, molecular mechanisms of Cdx2 induced leukemogenesis are poorly understood. One obvious possibility is that CDX2 exerts its leukemogenic potential by deregulating expression of leukemogenic genes of the HOXA and HOXB cluster, known to be dysregulated in 65% of all AML cases, in particular in normal karyotype (CN-AML) and MLL rearranged AML [55] [56] (Fig. 2) . This would classify the CDX-HOX axis as one of the major driving forces in human AML. However, it could be clearly demonstrated that aberrant Cdx2 expression, besides Hox deregulation, also led to an altered expression of a number of genes involved in embryonic development, lymphopoiesis, Wnt pathway and genes involved in stem cell function. These data support the hypothesis that Cdx2 might deregulate multiple pathways in leukemia, which would also explain the differences between Cdx2 and Cdx4 with regard to their leukemogenic potential.
So far strategies to target Cdx2-induced transformation remain elusive. One possibility would be to identify druggable signaling pathways on which Cdx2 activity are dependent.
Interestingly, it was shown in a colon cancer cell line that the transcriptional activity of Cdx2 depends on phosphorylation of the N-terminal S60 site by ERK kinases. We have shown that the N-terminal activation domain of Cdx2, at which the S60 site is localized, is essential for Cdx2 induced leukemogenesis and perturbation of Hox gene expression 55 . Recent studies documented that Erk1/2 and their upstream effectors Mek1/2 are constitutively activated in primary human AML cells 72 73-74 . Elevated p-ERK levels were found in 83.3% of the AML patients 75 . As aberrant expression of CDX2 is detected in 1 7 80% of all AML cases regulation of Cdx2 could be indirectly or directly linked with MEK/ERK signaling 72, 76 ( Fig. 3a,b) . Therefore, it will be interesting to test whether posttranscriptional modification of CDX2 is crucial for its leukemogenic properties and whether MAPK inhibitors are able to block Cdx2 induced leukemogenesis.
Another possibility to block Cdx2-induced leukemogenesis would be to inhibit mechanisms, which induce and maintain aberrant Cdx2 expression. However, mechanisms that lead to aberrant expression of CDX2 in leukemogenesis are still a mystery. As demonstrated by Scholl et al., the methylation levels of the promoter region of CDX2 in AML patients did not correspond to its expression levels 56 . In addition, treatment of CDX2-negative cell lines with demethylating agents did not lead to an induction of CDX2 expression 77 , suggesting that CDX2 expression in leukemia is independent of promoter hypomethylation as well as of the methylation level of cisregulatory elements. Amplification of the CDX2 locus was detected only in a small percentage of patients with complex karyotype, however not in AML patients with normal karyotype, which are characterized by high CDX2 expression levels 56, 78 . Another possibility, leading to aberrant transcription of CDX2 could be deregulation of transacting pathways, which target cis-regulatory elements in the 5' region of the CDX2 gene as suggested by Hinoi et al. 77 . However, it was reported that CDX2 expression is monoallelic in most of the analyzed leukemia patients 56 , which indicates that the altered CDX2 expression is not primarily due to differences in the expression of trans-acting factors but rather due to altered cis-regulatory elements, which affect only one allele.
Mutations were not detected in the promoter region of CDX2. However, this does not exclude still unknown mutations in cis-regulatory elements of the CDX2 gene, which (Fig. 3) .
Conclusion
In summary, there is a great body of evidence that ParaHox genes play a pivotal role in normal hematopoiesis, but also in leukemogenesis. These data add another homeobox gene family to the growing number of homeobox genes known to be critically involved in 1 9 orchestrating normal hematopoiesis and promoting leukemogenesis. Thus, the story 'homeobox genes in normal and malignant hematopoiesis' is not at its end but is still growing rapidly since the last review on this topic in this journal nearly 10 years ago 1 . In these 10 years dysregulation of homeobox genes has been recognized as one of the molecular hallmarks of human AML. We know today that homeobox genes are key players for determining 'stemness' and are essential for initiating and maintaining selfrenewal programs on which leukemic stem cell function depends For personal use only. on September 13, 2017. by guest www.bloodjournal.org From 0
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